X
<

Pfizer’s 2017 Performance in Review

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 12
Pfizer’s 2017 Performance in Review PART 12 OF 12

Pfizer on the Street: Analyst Recommendations in February 2018

PFE’s recent developments

In January 2017, Pfizer (PFE) and Sangamo Therapeutics (SGMO) entered into a collaboration agreement for the development of a potential gene therapy utilizing ZFP-TFs (zinc finger protein transcription factors) for the treatment of ALS (amyotrophic lateral sclerosis) and FTLD (frontotemporal lobar degeneration) linked to mutations of the C9ORF72 gene.

According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.

Pfizer on the Street: Analyst Recommendations in February 2018

Interested in PFE? Don't miss the next report.

Receive e-mail alerts for new research on PFE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Sangamo therapeutics will also receive development and commercial milestone payments of up to $150 million, along with royalties on sales revenues.

With this agreement, Pfizer is expected to establish a strong foothold in gene therapy.

PFE’s analyst recommendations

Of the 23 analysts tracking Pfizer (PFE) stock in February 2018, two recommended a “strong buy,” while ten analysts recommended a “buy.” Nine analysts recommended a “hold,” while two analysts recommended a “strong sell” for Pfizer stock.

On February 12, 2018, Pfizer had consensus 12-month target price of $40.25, which represents ~16.5% return on investment over the next 12 months.

Peer recommendations and ratings

By comparison, of the 23 analysts tracking Johnson & Johnson (JNJ) stock in February 2018, ~52% of the analysts recommended some form of a “buy.” On February 12, 2018, Johnson & Johnson had a consensus 12-month target price of $14.77, which represents a ~14.8% return on investment over the next 12 months.

Of the 22 analysts tracking Merck (MRK) stock in February, around 59% of the analysts recommended some form of a “buy.” On February 12, 2018, Merck had consensus 12-month target price of $67.0, which represents a ~20.1% return on investment over the next 12 months.

For ongoing updates on Pfizer and its industry peers, keep checking in with Market Realist’s Pharmaceuticals page.

X

Please select a profession that best describes you: